medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Number 1

<< Back Next >>

Ann Hepatol 2012; 11 (1)

Cytokines as important playmakers of experimental hepatocarcinogenesis confounded by diabetes

Abdel-Hamid NM, Nazmy MH, Abdel-Ghany MI, Nazmy WH

Language: English
References: 65
Page: 118-127
PDF size: 464.40 Kb.


ABSTRACT

Purpose. To explore the possible intermediary pathways through which diabetes mellitus (DM) adversely worsens hepatocellular carcinoma (HCC), focusing on cell life controllers as some transcription factors and inflammatory mediators. Material and methods. Forty male albino rats were divided into four groups, control, cancer [given single intra-peritoneal (IP) dose of diethyl nitrosamine, NDEA, 125 mg/kg body weight], diabetic (given single dose of streptozotocin, STZ, 65 mg/kg) and cancer diabetic. HCC was initiated with NDEA, 3 weeks later, DM was induced with STZ. At 14th week, animals were sacrificed. Serum ALT, AST, GGT activities, AFP, IL-6, TNF-α levels and liver tissue Bax and Bcl2 proteins were measured. Liver sections were stained for histological examination. Both histological and AFP variations were chosen to prove cancer development. Results. NDEA group showed significant increase in liver weight, serum ALT, AST, GGT, AFP, TNF-α, IL-6 and liver Bcl2 protein with decrease in total body weight, liver Bax protein and Bax/Bcl2 ratio. These effects were more pronounced in DENA plus STZ group. IL-6, TNF-α and Bcl2 were positively correlated while Bax and Bax/Bcl2 ratio were negatively correlated to AFP levels reflecting potential diagnostic value. Conclusion. Co-induction of DM in the course of hepatocarcinogenesis can dramatically influence disease progression through inflammation and retarded apoptosis. The suggested apoptotic and inflammatory markers seem to be beneficial diagnostic tools for HCC and improve the diagnostic performance of AFP.


REFERENCES

  1. El-Serag HB. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 87-107, vi.

  2. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002; 35: S72-S78.

  3. Srivatanakul P, Sriplung H, Deerasamee S. Epidemiology of liver cancer: an overview. Asian Pac J Cancer Prev 2004; 5: 118-25.

  4. Blum HE. Hepatocellular carcinoma: therapy and prevention. World J Gastroenterol 2005; 11: 7391-400.

  5. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003; 37: 429-42.

  6. Abdel-Hamid NM. Recent insights on risk factors of Hepatocellular carcinoma. World J Hepatol 2009a; 15: 3-7.

  7. Tang ZY. Hepatocellular carcinoma-cause, treatment and metastasis. World J Gastroenterol 2001; 7: 445-54.

  8. Yu AS, Keeffe EB. Management of hepatocellular carcinoma. Rev Gastroenterol Disord 2003; 3: 8-24.

  9. Hassan MM, Hwang LY, Hatten CJ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002; 36: 1206-13.

  10. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003; 22: 5093-107.

  11. Suriawinata A, Xu R. An update on the molecular genetics of hepatocellular carcinoma. Semin Liver Dis 2004; 24: 77-88.

  12. Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004; 127: S56-S61.

  13. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004; 127: S72-S78.

  14. el-Zayadi AR, Badran HM, Barakat EM, et al. Hepatocellular carcinoma in Egypt: a single center study over a decade. World J Gastroenterol 2005; 11: 5193-8.

  15. Tazawa J, Maeda M, Nakagawa M, et al. Diabetes mellitus may be associated with hepatocarcinogenesis in patients with chronic hepatitis C. Dig Dis Sci 2002; 47: 710-5.

  16. Hassan MM, Frome A, Patt YZ, El-Serag HB. Rising prevalence of hepatitis C virus infection among patients recently diagnosed with hepatocellular carcinoma in the United States. J Clin Gastroenterol 2002; 35: 266-9.

  17. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54: 533-9.

  18. Fabregat I. Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 2009; 15: 513-20.

  19. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. British J Cancer 1972; 26: 239-57.

  20. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003; 3: 745-56.

  21. Shi-Yong S. Apoptosis as a novel target for cancer chemoprevention. J National Cancer Institute 2004; 96: 662-72.

  22. Guicciardi ME, Gores GJ. Apoptosis: a mechanism of acute and chronic liver injury. Gut 2005; 54: 1024-33.

  23. Schattenberg JM, Galle PR, Schuchmann M. Apoptosis in liver disease. Liver Int 2006; 26: 904-11.

  24. Zhao Y, Li S, Childs EE, Kuharsky DK, Yin XM. Activation of pro-death Bcl-2 family proteins and mitochondria apoptosis pathway in tumor necrosis factor-alpha-induced liver injury. J Biol Chem 2001; 276: 27432-40.

  25. Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature 2004; 431: 405-6.

  26. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45.

  27. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 2002; 13: 135-41.

  28. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211-7.

  29. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006; 72: 1605-21.

  30. Saha BK, Sarkar A, Basak R, Chatterjee M. 1alpha, 25-Dihydroxyvitamin D3 suppresses the effect of streptozotocin- induced diabetes during chemical rat liver carcinogenesis. Cell Biol Int 2001; 25: 227-37.

  31. Van Gieson I. Van Gieson stain. In: Theory and practice of histological techniques. Churchill Livingstone Edinburgh; 1982.

  32. Chanas SA, Jiang Q, McMahon M, et al. Loss of the Nrf2 transcription factor causes a marked reduction in constitutive and inducible expression of the glutathione S-transferase Gsta1, Gsta2, Gstm1, Gstm2, Gstm3 and Gstm4 genes in the livers of male and female mice. Biochem J 2002; 365: 405-16.

  33. Sell S, Becker FF. alpha-Fetoprotein. J Natl Cancer Inst 1978; 60: 19-26.

  34. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.

  35. Lagiou P, Kuper H, Stuver SO, Tzonou A, Trichopoulos D, Adami HO. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 2000; 92: 1096-9.

  36. Yuan JM, Govindarajan S, Arakawa K, Yu MC. Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S. Cancer 2004; 101: 1009-17.

  37. Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology 2006; 43: 1295-302.

  38. Rousseau MC, Parent ME, Pollak MN, Siemiatycki J. Diabetes mellitus and cancer risk in a population-based casecontrol study among men from Montreal, Canada. Int J Cancer 2006; 118: 2105-9.

  39. Awadallah A, Issa, HA and Soliman, MS. Evaluation of Serum Chromogranin A as a Useful Tumor Marker for Diagnosis of Hepatocellular Carcinoma. J Am Sci 2011; 7: 999-1007.

  40. Bhattacharya N. A new experimental model of rat hepatocellular carcinoma. Exp Oncol 2003; 25: 55-9.

  41. Jagan S, Ramakrishnan G, Anandakumar P, Kamaraj S, Devaki T. Antiproliferative potential of gallic acid against diethylnitrosamine-induced rat hepatocellular carcinoma. Mol Cell Biochem 2008; 319: 51-9.

  42. Yao D, Jiang D, Huang Z, et al. Abnormal expression of hepatoma specific gamma-glutamyl transferase and alteration of gamma-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer 2000; 88: 761-9.

  43. Joyce-Brady M, Jean JC, Hughey RP. gamma -glutamyltransferase and its isoform mediate an endoplasmic reticulum stress response. J Biol Chem 2001; 276: 9468-77.

  44. Yao DF, Dong ZZ, Yao DB, et al. Abnormal expression of hepatoma-derived gamma-glutamyltransferase subtyping and its early alteration for carcinogenesis of hepatocytes. Hepatobiliary Pancreat Dis Int 2004; 3: 564-70.

  45. Volkmann M, Schiff JH, Hajjar Y, et al. Loss of CD95 expression is linked to most but not all p53 mutants in European hepatocellular carcinoma. J Mol Med 2001; 79: 594-600.

  46. Bruix J, Hessheimer AJ, Forner A, Boix L, Vilana R, Llovet JM. New aspects of diagnosis and therapy of hepatocellular carcinoma. Oncogene 2006; 25: 3848-56.

  47. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: balancing life and death—a new approach to cancer therapy. J Clin Invest 2005; 115: 2625-32.

  48. Owen JL, Iragavarapu-Charyulu V, Lopez DM. T cell-derived matrix metalloproteinase-9 in breast cancer: friend or foe? Breast Dis 2004; 20: 145-53.

  49. Abdel-Hamid NM. Premalignant variations in extracellular matrix composition in chemically induced hepatocellular carcinoma in rats. J Membr Biol 2009b; 230: 155-62.

  50. Mantovani A. Cancer: inflammation by remote control. Nature 2005; 435: 752-3.

  51. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-59.

  52. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.

  53. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2002; 2: 301-10.

  54. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006; 441: 431-6.

  55. Tapia MA, Gonzalez-Navarrete I, Dalmases A, et al. Inhibition of the canonical IKK/NF kappa B pathway sensitizes human cancer cells to doxorubicin. Cell Cycle 2007; 6: 2284-92.

  56. Wullaert A, van Loo G, Heyninck K, Beyaert R. Hepatic tumor necrosis factor signaling and nuclear factor-kappaB: effects on liver homeostasis and beyond. Endocr Rev 2007; 28: 365-86.

  57. Singh S, Shi Q, Bailey ST, et al. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor- negative and epidermal growth factor receptor family receptor-positive human breast cancer. Mol Cancer Ther 2007; 6: 1973-82.

  58. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-19.

  59. O’Brien RM, Granner DK. Regulation of gene expression by insulin. Biochem J 1991; 278(Pt. 3): 609-19.

  60. Brown-Borg HM, Rakoczy SG. Glutathione metabolism in long-living Ames dwarf mice. Exp Gerontol 2005; 40: 115-20.

  61. Asnaghi V, Gerhardinger C, Hoehn T, Adeboje A, Lorenzi M. A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes 2003; 52: 506-11.

  62. Graves DT, Liu R, Alikhani M, Al-Mashat H, Trackman PC. Diabetes-enhanced inflammation and apoptosis— impact on periodontal pathology. J Dent Res 2006; 85: 15-21.

  63. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol 2000; 130: 963-74.

  64. Dagher Z, Park YS, Asnaghi V, Hoehn T, Gerhardinger C, Lorenzi M. Studies of rat and human retinas predict a role for the polyol pathway in human diabetic retinopathy. Diabetes 2004; 53: 2404-11.

  65. Xu X, Zhu Q, Xia X, Zhang S, Gu Q, Luo D. Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin- induced diabetic rats. Curr Eye Res 2004; 28: 251-6.




2020     |     www.medigraphic.com